NASDAQ:MYOS - MYOS Stock Price, Price Target & More

$1.26 +0.03 (+2.44 %)

(As of 04/24/2018 04:00 PM ET)

Previous Close$1.23

Today's Range$1.24 - $1.26

52-Week Range$1.03 - $2.85

Volume10,720 shs

Average Volume114,644 shs

Market Capitalization$8.23 million

P/E Ratio-1.80

Dividend YieldN/A

Beta1.47

About MYOS (NASDAQ:MYOS)

MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Website remusclehealth.com; and Qurr line of products through convenient direct online ordering without a prescription. MYOS RENS Technology Inc. has a research agreement with the University of California to study the effects Of FortetropinÂ on skeletal muscle protein synthetic rate in older men and women; and Rutgers University for the discovery development and commercialization of products that improve muscle health and performance. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.

Receive MYOS News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:MYOS

CUSIPN/A

Webwww.myoscorp.com

Phone973-509-0444

Debt

Debt-to-Equity RatioN/A

Current Ratio6.65%

Quick Ratio2.53%

Price-To-Earnings

Trailing P/E Ratio-1.80

Forward P/E Ratio-3.82

P/E GrowthN/A

Sales & Book Value

Annual Sales$530,000.00

Price / Sales15.41

Cash FlowN/A

Price / CashN/A

Book Value$0.69 per share

Price / Book1.83

Profitability

EPS (Most Recent Fiscal Year)($0.69)

Net Income$-4,050,000.00

Net Margins-771.48%

Return on Equity-81.12%

Return on Assets-74.73%

Miscellaneous

Employees10

Outstanding Shares6,480,000

How to Become a New Pot Stock Millionaire

MYOS (NASDAQ:MYOS) Frequently Asked Questions

What is MYOS's stock symbol?

MYOS trades on the NASDAQ under the ticker symbol "MYOS."

How were MYOS's earnings last quarter?

MYOS Co. (NASDAQ:MYOS) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter. The business earned $0.16 million during the quarter. MYOS had a negative return on equity of 81.12% and a negative net margin of 771.48%. View MYOS's Earnings History.

When is MYOS's next earnings date?

MYOS is scheduled to release their next quarterly earnings announcement on Friday, May, 11th 2018. View Earnings Estimates for MYOS.

Who are some of MYOS's key competitors?

Some companies that are related to MYOS include OvaScience (OVAS), TapImmune (TPIV), Citius Pharmaceuticals (CTXR), Emisphere Technologies (EMIS), Ceapro (CRPOF), Nuvo Pharmaceuticals (NRIFF), Provectus Biopharmaceuticals (PVCT), Kitov Pharma (KTOV), Diffusion Pharmaceuticals (DFFN), Pernix Therapeutics (PTX), Jaguar Health (JAGX), Innovus Pharmaceuticals (INNV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST) and AEterna Zentaris (AEZS).

Who are MYOS's key executives?

MYOS's management team includes the folowing people:

Dr. Robert Joseph Hariri, Exec. Chairman & Chairman of the Scientific Advisory Board (Age 59)
Mr. Joseph Mannello, CEO & Director (Age 60)
Mr. Ren Ren, Global Chairman (Age 56)
Mr. Joseph DiPietro, Controller
Mr. Magshoud Dariani, Chief Technology Officer

Has MYOS been receiving favorable news coverage?

Headlines about MYOS stock have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MYOS earned a daily sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the company an impact score of 46.32 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of MYOS?

Shares of MYOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MYOS's stock price today?

One share of MYOS stock can currently be purchased for approximately $1.26.

How big of a company is MYOS?

MYOS has a market capitalization of $8.23 million and generates $530,000.00 in revenue each year. The company earns $-4,050,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. MYOS employs 10 workers across the globe.

How can I contact MYOS?

MYOS's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 973-509-0444 or via email at [email protected]

MarketBeat Community Rating for MYOS (MYOS)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		45 (Vote Outperform)
Underperform Votes:		42 (Vote Underperform)
Total Votes:		87

MarketBeat's community ratings are surveys of what our community members think about MYOS and other stocks. Vote "Outperform" if you believe MYOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOS will underperform the S&P 500 over the long term. You may vote once every thirty days.

MYOS (NASDAQ:MYOS) Analyst Ratings History

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details

(Data available from 4/24/2016 forward)

MYOS (NASDAQ:MYOS) Earnings History and Estimates Chart

Earnings by Quarter for MYOS (NASDAQ:MYOS)

MYOS (NASDAQ:MYOS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.32)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.08)	($0.08)	($0.08)
Q2 2018	1	($0.08)	($0.08)	($0.08)
Q3 2018	1	($0.09)	($0.09)	($0.09)
Q4 2018	1	($0.07)	($0.07)	($0.07)

MYOS (NASDAQ MYOS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/11/2018
11/14/2017	Q3 2017		($0.13)		$0.16 million	View	N/A
8/14/2017	Q2 2017		($0.19)		$0.06 million	View	N/A
5/12/2017	Q1 2017		($0.20)		$0.15 million	View	N/A
3/30/2017	Q4 2016		($0.14)		$0.03 million	View	N/A
11/14/2016	Q3 2016		($0.17)		$0.04 million	View	N/A
8/12/2016	Q2 2016		($0.30)		$0.07 million	View	N/A
5/13/2016	Q1 2016		($0.31)		$0.20 million	View	N/A
5/14/2015	Q1 2015		($0.50)		$0.01 million	View	N/A
11/14/2014	Q3 2014	($0.24)	($0.73)	$1.90 million	$0.11 million	View	N/A
8/14/2014	Q214	($0.20)	($0.32)	$1.70 million	$1.68 million	View	N/A
5/16/2014	Q1 2014		($0.16)		$1.55 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

MYOS (NASDAQ:MYOS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

MYOS (NASDAQ MYOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 45.70%
Institutional Ownership Percentage: 2.36%

Insider Trading History for MYOS (NASDAQ:MYOS)

MYOS (NASDAQ MYOS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/21/2017	Joseph Mannello	CEO	Buy	20,336	$1.46	$29,690.56	274,765
12/8/2017	Joseph Mannello	CEO	Buy	38,119	$1.35	$51,460.65	233,629
12/6/2017	Joseph Mannello	CEO	Buy	16,819	$1.35	$22,705.65	233,629
11/16/2017	Joseph Mannello	CEO	Buy	25,000	$1.31	$32,750.00	203,560
11/14/2017	Joseph Mannello	CEO	Buy	11,750	$1.27	$14,922.50	203,560
9/23/2016	Zhengguang Lyu	Director	Buy	50,000	$1.70	$85,000.00	83,505
9/6/2016	Zhengguang Lyu	Director	Buy	23,505	$1.60	$37,608.00	10,600
6/17/2016	Zhengguang Lyu	Director	Buy	10,000	$1.65	$16,500.00	10,000
4/8/2016	Joseph Mannello	Director	Buy	4,417	$1.96	$8,657.32	177,879
4/5/2016	Joseph Mannello	Director	Buy	6,128	$1.75	$10,724.00	170,962
9/29/2015	Robert J. Hariri	Director	Buy	2,300	$2.68	$6,164.00	92,364
9/25/2015	Robert J. Hariri	Director	Buy	12,150	$2.44	$29,646.00	90,064
9/11/2015	Robert J. Hariri	Director	Buy	4,000	$1.73	$6,920.00	77,914
9/8/2015	Robert J. Hariri	Director	Buy	25,250	$1.71	$43,177.50	73,914
9/4/2015	Louis J Aronne	Director	Buy	5,000	$1.76	$8,800.00	22,200
8/28/2015	Robert J Hariri	Director	Buy	2,750	$1.74	$4,785.00	48,664
12/4/2014	Robert J Hariri	Director	Buy	2,200	$8.16	$17,952.00
8/18/2014	Peter Diamandis	Director	Buy	3,444	$14.51	$49,972.44

(Data available from 1/1/2013 forward)

MYOS (NASDAQ MYOS) News Headlines

Source:

Date	Headline
	Free Research Report as Lipocine Announced FY17 Financial Results finance.yahoo.com - April 20 at 8:15 AM
	MYOS: A New Product For Sports Nutrition finance.yahoo.com - April 12 at 5:50 PM
	Was MYOS RENS Technology Inc’s (NASDAQ:MYOS) Earnings Growth Better Than The Industry’s? finance.yahoo.com - April 10 at 5:36 PM
	MYOS RENS Technology introduces a new sports nutrition product line, Yolked seekingalpha.com - April 10 at 8:14 AM
	MYOS RENS Technology Introduces New Sports Nutrition Product Line, Yolked™, and Earns Prestigious "Certified For Sport®" Certification From NSF International finance.yahoo.com - April 10 at 8:14 AM
	MYOS RENS Technology (MYOS) Upgraded by ValuEngine to Sell www.americanbankingnews.com - April 9 at 11:35 AM
	Detailed Research: Economic Perspectives on VASCO Data Security International, Constellation Brands www.nasdaq.com - April 6 at 8:15 AM
	Detailed Research: Economic Perspectives on VASCO Data Security International, Constellation Brands, MYOS RENS Technology, Avadel Pharmaceuticals, Energizer, and BJ's Restaurants — What Drives Growth in Today's Competitive Landscape finance.yahoo.com - April 6 at 8:15 AM
	Equities Analysts Offer Predictions for MYOS RENS Technology Inc's Q1 2018 Earnings (MYOS) www.americanbankingnews.com - April 5 at 7:38 AM
	MYOS RENS Technology to Present at the MicroCap Conference April 10 in New York City at the Essex House finance.yahoo.com - April 3 at 5:42 PM
	MYOS: Initiation Report finance.yahoo.com - April 3 at 5:42 PM
	MYOS RENS Technology CEO Joseph Mannello Provides Comments On Operational And Financial Results For Fiscal Year 2017 finance.yahoo.com - March 28 at 5:27 PM
	BRIEF-Myos Rens Says Qtrly Net Loss Rose 44 Pct To $1.1 MLN www.reuters.com - March 28 at 8:17 AM
	MYOS RENS Technology Inc. to Host Earnings Call finance.yahoo.com - March 28 at 8:17 AM
	MYOS RENS Technology Reports Fourth Quarter And Fiscal 2017 Financial Results www.prnewswire.com - March 27 at 6:19 PM
	MYOS RENS Technology (MYOS) Scheduled to Post Earnings on Thursday www.americanbankingnews.com - March 22 at 1:16 AM
	MYOS RENS Technology Announces the Date for the Release of Fourth Quarter and Year Ended December 31, 2017 Results, Conference Call and Webcast finance.yahoo.com - March 20 at 5:25 PM
	MYOS RENS Technology to Showcase Fortetropin® and the Qurr® Line of Muscle Health Products at the 2018 Arnold Sports Festival in Columbus, OH from March 2-4, 2018 finance.yahoo.com - February 15 at 8:56 AM
	MYOS RENS Technology (MYOS) Upgraded by ValuEngine to "Sell" www.americanbankingnews.com - February 4 at 9:14 PM
	MYOS RENS Technology Launches 30-Day Qurr® Fortetropin® Challenge www.prnewswire.com - January 16 at 6:24 AM
	MYOS RENS Technology CEO Issues Shareholder Letter finance.yahoo.com - January 11 at 9:52 AM
	Insider Buying: MYOS RENS Technology Inc (MYOS) CEO Purchases 20,336 Shares of Stock www.americanbankingnews.com - December 26 at 6:20 PM
	Insider Buying: MYOS RENS Technology Inc. (MYOS) CEO Buys 16,819 Shares of Stock www.americanbankingnews.com - December 8 at 11:16 PM
	Insider Buying: MYOS RENS Technology Inc. (MYOS) CEO Buys 38,119 Shares of Stock www.americanbankingnews.com - December 8 at 8:52 PM
	MYOS RENS Technology Enters Into Research Agreement With University Of California, Berkeley To Study Effects Of Fortetropin® On Skeletal Muscle Protein Synthetic Rate In Older Men And Women finance.yahoo.com - December 6 at 9:42 AM
	MYOS RENS Technology Inc. (MYOS) CEO Acquires $14,922.50 in Stock www.americanbankingnews.com - November 16 at 9:44 PM
	MYOS RENS Technology Inc. (MYOS) CEO Acquires $32,750.00 in Stock www.americanbankingnews.com - November 16 at 9:24 PM
	MYOS RENS Technology Inc. (MYOS) Releases Earnings Results www.americanbankingnews.com - November 15 at 1:05 PM
	MYOS RENS Technology Reports Third Quarter 2017 Financial Results finance.yahoo.com - November 15 at 6:38 AM
	MYOS RENS Technology Inc. Launches Collegiate Sports Marketing Platform finance.yahoo.com - November 9 at 6:46 AM
	Who Really Owns MYOS RENS Technology Inc (MYOS)? finance.yahoo.com - November 4 at 6:53 AM
	An Initiative To Promote Muscle Health And Its Importance In Fighting Aging And Speeding Up Post Workout Recovery globenewswire.com - October 27 at 8:16 AM
	Pro Football Legends, the Commercial Marketing Arm of the NFL Alumni, Launches Partnership with MYOS RENS Technology Inc. in Optimal Bowl and Wellness Challenge finance.yahoo.com - October 27 at 8:16 AM
	BRIEF-Myos Rens Technology Inc appoints Joseph Mannello as permanent CEO www.reuters.com - September 22 at 10:00 AM
	MYOS RENS Technology Inc. Appoints Joseph Mannello as Permanent Chief Executive Officer finance.yahoo.com - September 22 at 10:00 AM
	MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 finance.yahoo.com - August 25 at 8:58 AM
	MYOS RENS to Introduce the Qurr® Line of Muscle Health Products at 35th IDEA World Convention July 19-23, 2017 in Las Vegas finance.yahoo.com - July 13 at 7:06 AM
	How These Generic Drugs Stocks are Faring? -- MYOS RENS Technology, Akari Therapeutics, Flexion Therapeutics, and Zynerba Pharma www.prnewswire.com - May 19 at 7:13 PM
	MYOS RENS Technology to host April 4 interactive conference call on "Qurr" product launch us.rd.yahoo.com - March 31 at 9:26 AM
	MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex biz.yahoo.com - February 21 at 6:13 PM
	MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Ri us.rd.yahoo.com - February 15 at 2:17 AM
	MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, F biz.yahoo.com - February 8 at 7:36 PM
	2:55 pm MYOS RENS Tech. commences $2.125 common stock offering; to sell 500k shares at $4.25/share us.rd.yahoo.com - February 4 at 5:31 AM
	MYOS RENS TECHNOLOGY INC www.finanznachrichten.de - February 4 at 12:30 AM
	MYOS RENS Tech (MYOS) Reports $2.13M Registered Direct Offering of Common Stock www.streetinsider.com - February 3 at 7:28 PM
	MYOS RENS Technology Inc. Announces $2,125,000 Registered Direct Offering www.marketwatch.com - February 3 at 7:28 PM
	MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other biz.yahoo.com - January 11 at 7:21 PM
	MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders biz.yahoo.com - December 22 at 7:02 PM
	MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement biz.yahoo.com - November 25 at 11:34 AM
	BRIEF-Myos Rens Technology appoints Joseph Mannello interim CEO www.reuters.com - August 31 at 11:21 AM

MYOS (NASDAQ:MYOS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

MYOS (NASDAQ:MYOS) Income Statement, Balance Sheet and Cash Flow Statement

MYOS (NASDAQ MYOS) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff